Ursula Matulonis Md Shares Results Of The Soraya Study Broadcastmed Results: one hundred six patients were enrolled; 105 were evaluable for efficacy. all patients had received prior bevacizumab, 51% had three prior lines of therapy, and 48% received a prior poly adp ribose polymerase inhibitor. median follow up was 13.4 months. orr was 32.4% (95% ci, 23.6 to 42.2), including five complete and 29 partial responses. Ursula matulonis, md presented results of the soraya study at the 2022 society for gynecologic oncology annual meeting. the study examined the efficacy and safety of mirvetuximab soravtansine in patients with platinum resistant ovarian cancer with high folate receptor alpha expression.
Ursula Matulonis Md Shares Results Of The Soraya Study Broadcastmed Mirasol is a global randomized phase iii trial comparing mirv with standard single agent chemotherapy. 33 here, we report the findings from soraya, a single arm phase ii study evaluating the efficacy and safety of mirv in patients with frα high, platinum resistant, advanced high grade serous ovarian cancer. Results of the soraya study show conjugate therapy produced remissions in one third of patients with drug resistant ovarian cancer. Ursula a. matulonis, md. in an internationally conducted clinical trial lead by dana farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Soraya is a single arm, phase ii study evaluating efficacy and safety of mirv in patients with proc. methods soraya enrolled fra high patients with proc who had received one to three prior therapies,.
Ursula Matulonis Md New York Stem Cell Foundation Ursula a. matulonis, md. in an internationally conducted clinical trial lead by dana farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Soraya is a single arm, phase ii study evaluating efficacy and safety of mirv in patients with proc. methods soraya enrolled fra high patients with proc who had received one to three prior therapies,. Results: 106 pts were enrolled; 51% had 3 prior lines; 48% had 1 to 2 prior lines of therapy. all pts received prior bevacizumab; 48% received a prior parp inhibitor (parpi). median follow up time was 8.5 months at the data cutoff on november 16, 2021. Ursula matulonis, md presented results of the soraya study at the 2022 society for gynecologic oncology annual meeting. the study examined the efficacy and s. Ursula a. matulonis, md, spoke about the updated results of the phase 3 soraya trial with mirvetuximab soravtansine in patients with folate receptor α–high platinum resistant ovarian cancer presented at 2022 igcs. U. matulonis et al., “efficacy and safety of mirvetuximab soravtansine in patients with platinum resistant ovarian cancer with high folate receptor alpha expression : results from the soraya study,” journal of clinical oncology, vol. 41, no. 13, pp. 2436–2445, 2023.
Ursula A Matulonis Md Play For P I N K Results: 106 pts were enrolled; 51% had 3 prior lines; 48% had 1 to 2 prior lines of therapy. all pts received prior bevacizumab; 48% received a prior parp inhibitor (parpi). median follow up time was 8.5 months at the data cutoff on november 16, 2021. Ursula matulonis, md presented results of the soraya study at the 2022 society for gynecologic oncology annual meeting. the study examined the efficacy and s. Ursula a. matulonis, md, spoke about the updated results of the phase 3 soraya trial with mirvetuximab soravtansine in patients with folate receptor α–high platinum resistant ovarian cancer presented at 2022 igcs. U. matulonis et al., “efficacy and safety of mirvetuximab soravtansine in patients with platinum resistant ovarian cancer with high folate receptor alpha expression : results from the soraya study,” journal of clinical oncology, vol. 41, no. 13, pp. 2436–2445, 2023.